Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Walking away from cancer: study tests if exercise lowers recurrence risk

NCT ID NCT03975491

Knowledge-focused Sponsor: Pennington Biomedical Research Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at how moderate aerobic exercise (like brisk walking) might help prevent colorectal cancer from coming back. Researchers will measure changes in inflammation and other blood markers in 60 people who have finished cancer treatment. Participants either walk on a treadmill several times a week or continue their usual routine, and the study tracks biological changes over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
moderate-intensity aerobic exercise (treadmill walking)
What this could lead to
If successful, this could show that regular exercise after colorectal cancer treatment lowers inflammation and may reduce the chance of cancer coming back.
What could go wrong
This is a small, early-stage study (60 participants) looking at biological markers, not directly at cancer recurrence. Results may not prove exercise prevents recurrence, and individual results may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Aug 2019

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Histologically-confirmed stage I-III colorectal cancer * Completed surgical resection * Completed chemotherapy (if applicable) * Completed radiotherapy (if applicable) * Provide written approval by physician or other qualified healthcare provider * No planned major surgery during the study period (including colostomy reversal; chemotherapy infusion port removal is permitted) * Readiness to exercise \[as determined by a modified version the Physical Activity Readiness Questionnaire (PAR-Q) * Allow the collection and storage of specimens and data for future use * Willing to be randomized Exclusion Criteria: * Evidence of metastatic colon cancer * Concurrently actively treated other cancer (except non-melanoma skin cancer or in situ cancers) * Currently enrolled in another clinical trial of weight loss, physical activity, or dietary intervention * Current body mass greater than or equal to 181 kg * Unable to provide a baseline fasting blood sample * Unable or unwilling to give informed consent * Unable or unwilling to be randomized * Or any other condition that may impede testing of the study hypothesis or make it unsafe to engage in the exercise program (as determined by the investigative team)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm colorectal cancer rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colon cancer Rectal cancer

Contacts and locations

Locations

  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana, 70808, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.